Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Abpro Holdings Inc (ABPWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ABPWW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.54% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1055.19% |
Management Effectiveness
Return on Assets (TTM) -33.51% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3717658 |
Shares Outstanding - | Shares Floating 3717658 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Abpro Holdings Inc
Company Overview
History and Background
Abpro Holdings Inc. is a biopharmaceutical company focused on developing next-generation antibody therapies for cancer and other diseases. Founded in 2007, Abpro has progressed from early research and development to clinical-stage programs, partnering with larger pharmaceutical companies along the way. They've reached milestones in developing DiversImmuneu2122 platform, aimed at creating bispecific antibodies.
Core Business Areas
- Therapeutic Antibody Development: Develops proprietary therapeutic antibodies and antibody-based biologics for oncology, autoimmune, and infectious diseases. This includes research, preclinical, and clinical development.
- DiversImmuneu2122 Platform: The platform aims to generate bispecific antibodies and other novel antibody formats with enhanced therapeutic potential.
- Partnerships and Licensing: Collaborates with pharmaceutical companies through partnerships and licensing agreements to advance the development and commercialization of its products.
Leadership and Structure
The company's leadership team includes a CEO (Ian Chan) and other key executives responsible for R&D, clinical development, and business operations. The organizational structure involves various departments focused on research, manufacturing, and commercialization, with scientific advisory boards.
Top Products and Market Share
Key Offerings
- ABP-201: ABP-201 is a bispecific antibody therapeutic candidate targeting EGFR and CD3 for solid tumors. It is in Phase 1 clinical trials. Competitors include companies developing bispecific antibodies such as Amgen (AMG) and Roche (RHHBY).
- ABP-300: ABP-300 is a bispecific antibody program targeting multiple solid tumor targets. It's in preclinical development. Competitors include companies developing bispecific antibodies such as Regeneron (REGN).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for antibody therapies is expanding due to the increasing prevalence of cancer and autoimmune diseases. Advances in technology are driving the development of novel antibody formats, such as bispecific antibodies.
Positioning
Abpro is positioned as a biotech firm specializing in innovative antibody therapeutics. Its DiversImmune platform provides a competitive advantage in creating bispecific antibodies. The company focuses on partnerships and collaborations to leverage its technology and accelerate drug development.
Total Addressable Market (TAM)
The total addressable market for cancer antibody therapeutics is estimated to be in the tens of billions of dollars annually. Abpro aims to capture a portion of this market through its innovative antibody programs, especially with its bispecific antibody candidates. However, it currently faces significant competition from larger pharmaceutical companies.
Upturn SWOT Analysis
Strengths
- Proprietary DiversImmuneu2122 platform technology
- Bispecific antibody expertise
- Experienced management team
- Strategic partnerships with pharmaceutical companies
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on partnerships for late-stage development and commercialization
- Early stage clinical pipeline
- Negative EPS
Opportunities
- Growing market for antibody therapeutics
- Potential for strategic alliances and licensing agreements
- Advancements in antibody engineering technologies
- Expansion into new therapeutic areas
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
- Funding constraints
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
- REGN
- BMY
- MRK
Competitive Landscape
Abpro faces significant competition from larger pharmaceutical companies with greater financial resources and established market presence. Its competitive advantage lies in its DiversImmuneu2122 platform technology and focus on bispecific antibody therapeutics. Success is dependent on executing clinical trials, demonstrating superior efficacy, and securing partnerships to commercialize its products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress and securing partnerships rather than financial growth. Key milestones include advancing preclinical programs and initiating clinical trials.
Future Projections: Future growth is contingent on the successful completion of clinical trials, regulatory approvals, and commercialization of its antibody therapeutics. Analyst estimates anticipate potential revenue generation from product sales and royalties, contingent on clinical and regulatory success. These projections are highly uncertain.
Recent Initiatives: Recent initiatives include initiating Phase 1 clinical trials for ABP-201, advancing preclinical programs, and exploring strategic partnerships to accelerate drug development.
Summary
Abpro Holdings Inc. is a high-risk, high-reward biotechnology company focused on innovative antibody therapeutics. Its DiversImmune platform and bispecific antibody expertise represent its main strengths. However, its limited financial resources and reliance on partnerships pose challenges. Success hinges on clinical trial outcomes and securing strategic alliances.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q), Press Releases, Investor Presentations, Analyst Reports (where available).
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abpro Holdings Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2022-03-07 | CEO & Chairman of the Board Mr. Jin Wook Suk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://abpro.co |
Full time employees 6 | Website https://abpro.co | ||
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.